These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2528450)

  • 1. Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.
    Tuchman M; Roemeling RV; Hrushesky WA; Sothern RB; O'Dea RF
    Enzyme; 1989; 42(1):15-24. PubMed ID: 2528450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrimidine dehydrogenase activity in a Korean population.
    Sohn DR; Cho MS; Chung PJ
    Ther Drug Monit; 1999 Apr; 21(2):152-4. PubMed ID: 10217332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population study of dihydropyrimidine dehydrogenase in cancer patients.
    Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
    J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.
    Van Kuilenburg AB; Van Lenthe H; Tromp A; Veltman PC; Van Gennip AH
    Clin Chem; 2000 Jan; 46(1):9-17. PubMed ID: 10620566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus.
    Fleming GF; Vokes EE; Buse JB; Mick R; Dushay J; Levitan D; Dolan ME
    Cancer Chemother Pharmacol; 1996; 37(6):569-73. PubMed ID: 8612311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z; Zhang R; Diasio RB
    Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions.
    van den Wildenberg SAH; Streng AS; van den Broek R; Broeren MAC; Deenen MJ; van Dongen JLJ; Hanrath MA; Lapré C; Brunsveld L; Scharnhorst V; van de Kerkhof D
    J Pharm Biomed Anal; 2022 Nov; 221():115027. PubMed ID: 36099723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
    Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
    Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
    Grem JL; Yee LK; Venzon DJ; Takimoto CH; Allegra CJ
    Cancer Chemother Pharmacol; 1997; 40(2):117-25. PubMed ID: 9182832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.
    Johnson MR; Yan J; Shao L; Albin N; Diasio RB
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(2):183-91. PubMed ID: 9323539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity.
    van Kuilenburg AB; van Lenthe H; Zoetekouw L; Kulik W
    Clin Chem; 2007 Mar; 53(3):528-30. PubMed ID: 17272486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
    Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
    Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
    Ahmed FY; Johnston SJ; Cassidy J; O'Kelly T; Binnie N; Murray GI; van Gennip AH; Abeling NG; Knight S; McLeod HL
    J Clin Oncol; 1999 Aug; 17(8):2439-45. PubMed ID: 10561307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
    Ridge SA; Sludden J; Brown O; Robertson L; Wei X; Sapone A; Fernandez-Salguero PM; Gonzalez FJ; Vreken P; van Kuilenburg AB; van Gennip AH; McLeod HL
    Br J Clin Pharmacol; 1998 Aug; 46(2):151-6. PubMed ID: 9723824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
    Harris BE; Song R; Soong SJ; Diasio RB
    Cancer Res; 1990 Jan; 50(1):197-201. PubMed ID: 2293556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.